Endometrial Cancer – Pipeline Review, H2 2012

Published : July 2012
No. of Pages : 250

Price:

Endometrial Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, ''Endometrial Cancer - Pipeline Review, H2 2012'', provides an overview of the Endometrial Cancer therapeutic pipeline. This report provides information on the therapeutic development for Endometrial Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Endometrial Cancer. ''Endometrial Cancer - Pipeline Review, H2 2012'' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Endometrial Cancer.
- A review of the Endometrial Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Endometrial Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Endometrial Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Endometrial Cancer pipeline depth and focus of Endometrial Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Endometrial Cancer Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Endometrial Cancer 10
Endometrial Cancer Therapeutics under Development by Companies 12
Endometrial Cancer Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 19
Comparative Analysis 19
Mid Clinical Stage Products 20
Comparative Analysis 20
Early Clinical Stage Products 21
Comparative Analysis 21
Pre-Clinical Stage Products 22
Comparative Analysis 22
Endometrial Cancer Therapeutics – Products under Development by Companies 23
Endometrial Cancer Therapeutics – Products under Investigation by Universities/Institutes 25
Companies Involved in Endometrial Cancer Therapeutics Development 30
Bristol-Myers Squibb Company 30
Sanofi-Aventis 31
AstraZeneca PLC 32
GlaxoSmithKline plc 33
Genentech, Inc. 34
Daiichi Sankyo Company, Ltd 35
Merck & Co., Inc. 36
MediGene AG 37
Novartis AG 38
Eisai Co., Ltd. 39
Pfizer Inc. 40
EntreMed, Inc. 41
AEterna Zentaris Inc. 42
Critical Outcome Technologies Inc. 43
National Cancer Center 44
RXi Pharmaceuticals Corporation 45
Esperance Pharmaceuticals, Inc. 46
PharmaMar, S.A. 47
arGEN-X BV 48
Endometrial Cancer – Therapeutics Assessment 49
Assessment by Monotherapy Products 49
Assessment by Combination Products 50
Assessment by Route of Administration 51
Assessment by Molecule Type 53
Drug Profiles 56
AEZS-108 - Drug Profile 56
E7080 - Drug Profile 58
RG7422 - Drug Profile 60
PF-05212384 - Drug Profile 61
Ridaforolimus - Drug Profile 62
SAR245408 - Drug Profile 64
MKC-1 - Drug Profile 65
Faslodex - Drug Profile 67
BSI-201 - Drug Profile 68
COTI-2 - Drug Profile 70
EP-100 - Drug Profile 71
TKI258 - Drug Profile 73
Zalypsis - Drug Profile 75
L1 Monoclonal Antibody - Drug Profile 76
Bevacizumab + Temsirolimus - Drug Profile 78
Faslodex - Drug Profile 79
Trastuzumab - Drug Profile 80
Torisel + Caelyx - Drug Profile 81
EC145 - Drug Profile 83
Megestrol - Drug Profile 84
Vinorelbine + Paclitaxel + Radiation Therapy - Drug Profile 85
Paclitaxel - Drug Profile 87
AZD2171 + Temsirolimus - Drug Profile 89
Avastin + Radiation Therapy - Drug Profile 90
Fluorouracil + Doxorubicin - Drug Profile 91
Thalidomide - Drug Profile 92
Letrozole - Drug Profile 94
Carboplatin + Paclitaxel + Bevacizumab - Drug Profile 96
Carboplatin + Cisplatin + Paclitaxel + Radiation Therapy - Drug Profile 98
CCI-779 - Drug Profile 100
Ridaforolimus - Drug Profile 101
Alimta - Drug Profile 102
Medroxyprogesterone Acetate - Drug Profile 104
Paclitaxel + Carboplatin - Drug Profile 105
Ixabepilone - Drug Profile 106
Temsirolimus + Metformin - Drug Profile 108
Docetaxel - Drug Profile 109
RAD001 - Drug Profile 110
Carboplatin + Paclitaxel + Cisplatin + Radiation Therapy - Drug Profile 111
Bevacizumab - Drug Profile 112
CCI-779 - Drug Profile 114
BKM120 - Drug Profile 116
PF-04691502 - Drug Profile 118
Carboplatin + Paclitaxel + Avastin - Drug Profile 119
Paclitaxel + Carboplatin + Brachytherapy - Drug Profile 121
Carboplatin + Docetaxel + Radiation Therapy - Drug Profile 123
Taxotere + Paraplatin - Drug Profile 125
MGI-114 - Drug Profile 126
Ethinyl Estradiol + Norgestrel - Drug Profile 127
Medroxyprogesterone - Drug Profile 128
Erbitux - Drug Profile 129
Cisplatin + Paclitaxel + Radiation Therapy - Drug Profile 130
Carboplatin + Paclitaxel + Bevacizumab - Drug Profile 132
Paclitaxel + Carboplatin + Amifostine - Drug Profile 134
Sutent - Drug Profile 135
BMS582664 - Drug Profile 137
GW572016 - Drug Profile 138
Megestrol + Tamoxifen + Temsirolimus - Drug Profile 139
Bevacizumab + Carboplatin + Ixabepilone - Drug Profile 141
CCI-779 + Carboplatin + Paclitaxel - Drug Profile 143
5-Fluorouracil + Interferon-a + Doxorubicin + Hyperthermia - Drug Profile 145
Sunitinib - Drug Profile 146
Paclitaxel + Carboplatin + Megesterol Acetate - Drug Profile 147
Paclitaxel + Doxorubicin + Cisplatin + Filgrastim - Drug Profile 149
Letrozole - Drug Profile 151
Tarceva - Drug Profile 152
Carboplatin + Taxotere + Gemcitabine - Drug Profile 153
GSK1120212 + GSK2141795 - Drug Profile 155
Everolimus - Drug Profile 156
Carboplatin + Paclitaxel + Radiation Therapy - Drug Profile 157
Taxol - Drug Profile 158
Temsirolimus + Vinorelbine Ditartrate - Drug Profile 161
Doxorubicin + Cisplatin - Drug Profile 162
Docetaxel + Cisplatin - Drug Profile 163
COTI-2 + Abraxane - Drug Profile 164
Ixempra - Drug Profile 166
RO4929097 + Temsirolimus - Drug Profile 167
Docetaxel + Carboplatin - Drug Profile 168
AMG 386 - Drug Profile 169
Femara + RAD001 - Drug Profile 170
G-CSF + Cisplatin + Doxorubicin + Paclitaxel - Drug Profile 171
Filgrastim + Cisplatin + Doxorubicin Hydrochloride + Megestrol Acetate + Paclitaxel + Tamoxifen Citrate - Drug Profile 173
Taxol + Radiation Therapy - Drug Profile 176
Triapine + Cisplatin + Radiation Therapy - Drug Profile 177
Carboplatin + Doxorubicin + Paclitaxel - Drug Profile 179
CCI-779 + Carboplatin + Paclitaxel - Drug Profile 180
Bevacizumab + Carboplatin + Cisplatin + Paclitaxel - Drug Profile 182
Raloxifene - Drug Profile 184
Megace - Drug Profile 185
Pegylated Liposomal Doxorubicin Hydrochloride + Carboplatin - Drug Profile 186
Myocet + Carboplatin - Drug Profile 187
Carboplatin + Paclitaxel + Amifostine - Drug Profile 189
Carboplatin + Paclitaxel + Radiation Therapy - Drug Profile 191
Cisplatin - Drug Profile 193
Gemcitabine + Cisplatin - Drug Profile 194
Topotecan - Drug Profile 196
BIBF 1120 - Drug Profile 198
X-480 - Drug Profile 199
EP-200 - Drug Profile 200
Ridaforolimus + Taxol + Carboplatin - Drug Profile 201
Carboplatin + Paclitaxel - Drug Profile 203
DS-7423 - Drug Profile 205
Carboplatin + Paclitaxel + Herceptin - Drug Profile 206
²¹²Pb-TCMC-Trastuzumab - Drug Profile 208
ARGX-109 - Drug Profile 210
Folate Binding Protein E39 Targeted Vaccine - Drug Profile 211
BIBF 1120 - Drug Profile 212
Endometrial Cancer Therapeutics – Drug Profile Updates 213
Endometrial Cancer Therapeutics – Discontinued Products 229
Endometrial Cancer Therapeutics - Dormant Products 230
Endometrial Cancer – Product Development Milestones 234
Featured News & Press Releases 234
Appendix 242
Methodology 242
Coverage 242
Secondary Research 242
Primary Research 242
Expert Panel Validation 242
Contact Us 243
Disclaimer 243

List of Tables
Number of Products Under Development for Endometrial Cancer, H2 2012 17
Products under Development for Endometrial Cancer – Comparative Analysis, H2 2012 18
Number of Products under Development by Companies, H2 2012 20
Number of Products under Development by Companies, H2 2012 (Contd..1) 21
Number of Products under Investigation by Universities/Institutes, H2 2012 23
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 24
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 25
Comparative Analysis by Late Stage Development, H2 2012 26
Comparative Analysis by Mid Clinical Stage Development, H2 2012 27
Comparative Analysis by Early Clinical Stage Development, H2 2012 28
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 29
Products under Development by Companies, H2 2012 30
Products under Development by Companies, H2 2012 (Contd..1) 31
Products under Investigation by Universities/Institutes, H2 2012 32
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 33
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 34
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 35
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 36
Bristol-Myers Squibb Company, H2 2012 37
Sanofi-Aventis, H2 2012 38
AstraZeneca PLC, H2 2012 39
GlaxoSmithKline plc, H2 2012 40
Genentech, Inc., H2 2012 41
Daiichi Sankyo Company, Ltd, H2 2012 42
Merck & Co., Inc., H2 2012 43
MediGene AG, H2 2012 44
Novartis AG, H2 2012 45
Eisai Co., Ltd., H2 2012 46
Pfizer Inc., H2 2012 47
EntreMed, Inc., H2 2012 48
AEterna Zentaris Inc., H2 2012 49
Critical Outcome Technologies Inc., H2 2012 50
National Cancer Center, H2 2012 51
RXi Pharmaceuticals Corporation, H2 2012 52
Esperance Pharmaceuticals, Inc., H2 2012 53
PharmaMar, S.A., H2 2012 54
arGEN-X BV, H2 2012 55
Assessment by Monotherapy Products, H2 2012 56
Assessment by Combination Products, H2 2012 57
Assessment by Stage and Route of Administration, H2 2012 59
Assessment by Stage and Molecule Type, H2 2012 62
Endometrial Cancer Therapeutics – Drug Profile Updates 220
Endometrial Cancer Therapeutics – Discontinued Products 236
Endometrial Cancer Therapeutics – Dormant Products 237
Endometrial Cancer Therapeutics – Dormant Products (Contd..1) 238
Endometrial Cancer Therapeutics – Dormant Products (Contd..2) 239
Endometrial Cancer Therapeutics – Dormant Products (Contd..3) 240

List of Figures
Number of Products under Development for Endometrial Cancer, H2 2012 17
Products under Development for Endometrial Cancer – Comparative Analysis, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 22
Late Stage Products, H2 2012 26
Mid Clinical Stage Products, H2 2012 27
Early Clinical Stage Products, H2 2012 28
Pre-Clinical Stage Products, H2 2012 29
Assessment by Monotherapy Products, H2 2012 56
Assessment by Combination Products, H2 2012 57
Assessment by Route of Administration, H2 2012 58
Assessment by Stage and Route of Administration, H2 2012 59
Assessment by Molecule Type, H2 2012 60
Assessment by Stage and Molecule Type, H2 2012 61

Endometrial Cancer – Pipeline Review, H2 2012

Published By: Global Markets Direct

Price:

How to Purchase

Purchase products from our site in 5 easy steps. Please follow the description given below to complete your purchase process.

Step 1:

Select the report title of your interest, and Click on Buy Now button next to the Price option.

Step 2:

You will arrive at the Purchase page, where you will be requested to Signup (New User) or Login (Registered User). Please note that in-keeping with the security check on the website, you must submit your full details to avoid any inconvenience arising from incorrectly entered data or counterfeit information.

Step 3:

After SignUp/Login, you will arrive at the Online Invoice Page. Select a Payment option via various methods: Debit Card / Credit Card / by Invoice. MarketReportOnline accepts Visa, MasterCard, American Express and all major credit cards. MarketReportOnline uses ICICI, HDFC, Citibank, American Express & Paypal as our Online Payment Gateway Partners. Clicking on a payment option will take you to the corresponding Payment Gateway page.

Step 4:

Once at the Payment Gateway, please complete the Payment Process to purchase your desired report.

Step 5:

Once you have successfully completed the purchase process, you will receive a confirmation email. You will then either be able to download your report immediately (in PDF Format) from the Account Login button, or the report will be emailed to you directly, depending upon the agreement we have with the publisher. For Orders that are deliverable via email and placed after working hours, the delivery of the reports will be made on the next business day. Please note, if you select purchase by invoice, you will receive your report only once the payment has been received. If you have any queries about how to order, please Contact Us .

sales@marketreportsonline.com + 1 888 391 5441

Using our subscription option, you get access to market research reports and industry data of Industry Profiles market as per your needs. Get the best of Industry Profiles research reports by utilizing your research budgets in an optimum way.
More about our Subscription option

Get Email alerts about market research reports from industries and publishers of your interest: